Importance of 14-3-3eta, anti-CarP, and anti-Sa in the diagnosis of seronegative rheumatoid arthritis
This work is licensed under a Creative Commons Attribution 4.0 International License..
Background/aim: Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation. The study aimed to assess serum 14-3-3eta, anti-CarP, and anti-Sa in seronegative RA (SNRA) patients who were treatment-naïve as well as in healthy subjects. This is the first study in the literature to examine these autoantibodies together in SNRA patients.
Materials and methods: Forty-five treatment-naïve SNRA patients and 45 healthy subjects were recruited. Drugs change the levels of autoantibodies; therefore, patients who took any medication had been excluded from our study. Anti-carbamylated protein, anti-Sa, and 14-3-3eta were measured by using three different ELISA kits.
Results: Median serum concentration of healthy controls in 14-3-3eta was 0.02 (0.02–0.27) ng/mL. Median serum concentration of SNRA patients in 14-3-3eta was 1.00 (0.48–1.28) ng/mL. Data were analyzed with Mann–Whitney U tests; the P-value was <0.001 in 14-3-3eta. Receiver operating characteristic (ROC) curve analysis showed that 14-3-3eta in SNR compared to healthy controls had a significant (P < 0.001) area under the curve (AUC) of 0.90 (95% confidence interval, 0.83–0.96). At a cutoff of ≥0.33 ng/mL, the ROC curve yielded a sensitivity of 88.9%, a specificity of 82.2%, a positive predictive value of 83.3%, and a negative predictive value of 88.1%.
Conclusion: We found that 14-3-3eta can be used as a diagnostic marker in SNRA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Turkish journal of medical sciences - 49(2019), 5 vom: 24. Okt., Seite 1498-1502 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salman, Emrah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
14-3-3 Proteins |
|---|
| Anmerkungen: |
Date Completed 02.04.2020 Date Revised 13.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3906/sag-1812-137 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302560033 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302560033 | ||
| 003 | DE-627 | ||
| 005 | 20231225110958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3906/sag-1812-137 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1008.xml |
| 035 | |a (DE-627)NLM302560033 | ||
| 035 | |a (NLM)31651120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salman, Emrah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Importance of 14-3-3eta, anti-CarP, and anti-Sa in the diagnosis of seronegative rheumatoid arthritis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.04.2020 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This work is licensed under a Creative Commons Attribution 4.0 International License. | ||
| 520 | |a Background/aim: Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation. The study aimed to assess serum 14-3-3eta, anti-CarP, and anti-Sa in seronegative RA (SNRA) patients who were treatment-naïve as well as in healthy subjects. This is the first study in the literature to examine these autoantibodies together in SNRA patients | ||
| 520 | |a Materials and methods: Forty-five treatment-naïve SNRA patients and 45 healthy subjects were recruited. Drugs change the levels of autoantibodies; therefore, patients who took any medication had been excluded from our study. Anti-carbamylated protein, anti-Sa, and 14-3-3eta were measured by using three different ELISA kits | ||
| 520 | |a Results: Median serum concentration of healthy controls in 14-3-3eta was 0.02 (0.02–0.27) ng/mL. Median serum concentration of SNRA patients in 14-3-3eta was 1.00 (0.48–1.28) ng/mL. Data were analyzed with Mann–Whitney U tests; the P-value was <0.001 in 14-3-3eta. Receiver operating characteristic (ROC) curve analysis showed that 14-3-3eta in SNR compared to healthy controls had a significant (P < 0.001) area under the curve (AUC) of 0.90 (95% confidence interval, 0.83–0.96). At a cutoff of ≥0.33 ng/mL, the ROC curve yielded a sensitivity of 88.9%, a specificity of 82.2%, a positive predictive value of 83.3%, and a negative predictive value of 88.1% | ||
| 520 | |a Conclusion: We found that 14-3-3eta can be used as a diagnostic marker in SNRA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 14-3-3eta | |
| 650 | 4 | |a Anti-carP | |
| 650 | 4 | |a Anti Sa | |
| 650 | 4 | |a seronegative | |
| 650 | 7 | |a 14-3-3 Proteins |2 NLM | |
| 650 | 7 | |a Anti-Citrullinated Protein Antibodies |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Carbamates |2 NLM | |
| 650 | 7 | |a Vimentin |2 NLM | |
| 700 | 1 | |a Çetiner, Salih |e verfasserin |4 aut | |
| 700 | 1 | |a Boral, Barış |e verfasserin |4 aut | |
| 700 | 1 | |a Kibar, Filiz |e verfasserin |4 aut | |
| 700 | 1 | |a Erken, Eren |e verfasserin |4 aut | |
| 700 | 1 | |a Ersözlü, Emine Duygu |e verfasserin |4 aut | |
| 700 | 1 | |a Badak, Suade Özlem |e verfasserin |4 aut | |
| 700 | 1 | |a Bilici Salman, Reyhan |e verfasserin |4 aut | |
| 700 | 1 | |a Sertdemir, Yaşar |e verfasserin |4 aut | |
| 700 | 1 | |a Çetin Duran, Alev |e verfasserin |4 aut | |
| 700 | 1 | |a Yaman, Akgün |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Turkish journal of medical sciences |d 1997 |g 49(2019), 5 vom: 24. Okt., Seite 1498-1502 |w (DE-627)NLM093849745 |x 1303-6165 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2019 |g number:5 |g day:24 |g month:10 |g pages:1498-1502 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3906/sag-1812-137 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2019 |e 5 |b 24 |c 10 |h 1498-1502 | ||